Strategic Overview & Scientific Significance
Apoptosis Signal-regulating Kinase 1 (ASK1) inhibitors represent a premier frontier in targeted innovative drug research, holding monumental clinical value in addressing heavy unmet medical needs such as non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), advanced tissue fibrosis, and targeted oncology.
Our ASK1 Inhibitors Advanced Intermediates are meticulously engineered to satisfy the rigorous synthetic requirements of global pharmaceutical innovators. Featuring complex heterocyclic scaffolds, demanding stereoselective control, and rigorous impurity profiling, these high-barrier building blocks establish an elite moat against generic commoditization.
Technical Specifications & Purity Standard
Every commercial batch and pilot scale-up lot is produced under strict telemetry oversight and certified analytical verification to guarantee zero-defect laboratory execution.
| Parameter / Test Item | Standard Specification | Analytical Method |
|---|---|---|
| Chemical Purity | ≥ 99.0% (Customizable to ≥ 99.5%) | HPLC / GC |
| Individual Impurity | ≤ 0.1% (Strict Profiling) | HPLC Peak Area Normalized |
| Moisture Content | ≤ 0.1% (Ultra-Low Moisture) | Karl Fischer Titration |
| Residual Solvents | Complying with ICH Q3C Guidelines | Headspace GC |
| Appearance | Off-white to Crystalline Powder | Visual Inspection |
Supply Chain Stability
- Long-term clinical trial security (Phase II / III)
- Zero supply interruption during multi-year programs
- Complete IP protection and strict confidentiality
Custom Scale-Up Synergy
- Seamless transition from milligram R&D to kilogram pilot
- Supported by proprietary strong-base catalytic reagents (DBU/TMG)
- Dedicated senior chemist technical consultation